版本:
中国

BRIEF-Alexion submits application for soliris as treatment for refractory generalized myasthenia gravis

March 22 Alexion Pharmaceuticals Inc -

* Alexion submits application in Japan for soliris® (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gmg) Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐